Takeda Partners with MiTest Health to Launch Innovative Disease Risk Prediction Tool to Redefine Crohn’s Disease Management
LEXINGTON, Mass., Dec. 13, 2019 /PRNewswire/ — Takeda Pharmaceuticals U.S.A. (TSE: 4502) (NYSE:TAK) (“Takeda”) and MiTest Health LLC (“MiTest”), a pioneering health technology company, today announced...

